Mathieu, C., Wych, J., Hendriks, A. E. J., Van Ryckeghem, L., Tree, T., Chmura, P., . . . Marcovecchio, M. L. (2025). Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): A phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. The Lancet (British edition), 406(10510), 1375. https://doi.org/10.1016/S0140-6736(25)01674-5
Citace podle Chicago (17th ed.)Mathieu, Chantal, et al. "Minimum Effective Low Dose of Antithymocyte Globulin in People Aged 5-25 Years with Recent-onset Stage 3 Type 1 Diabetes (MELD-ATG): A Phase 2, Multicentre, Double-blind, Randomised, Placebo-controlled, Adaptive Dose-ranging Trial." The Lancet (British Edition) 406, no. 10510 (2025): 1375. https://doi.org/10.1016/S0140-6736(25)01674-5.
Citace podle MLA (9th ed.)Mathieu, Chantal, et al. "Minimum Effective Low Dose of Antithymocyte Globulin in People Aged 5-25 Years with Recent-onset Stage 3 Type 1 Diabetes (MELD-ATG): A Phase 2, Multicentre, Double-blind, Randomised, Placebo-controlled, Adaptive Dose-ranging Trial." The Lancet (British Edition), vol. 406, no. 10510, 2025, p. 1375, https://doi.org/10.1016/S0140-6736(25)01674-5.